These relatively new drugs , such as copyright and Semaglutide, are gaining traction for their effect in addressing type 2 diabetes and, increasingly , obesity . They belong to a category called GLP-1 https://henritpno635342.blognody.com/53693380/copyright-and-glp-1-receptor-agonists-everything-people-should-about